Achaogen Inc (NASDAQ:AKAO) insider Kenneth J. Hillan sold 4,606 shares of the stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $10.67, for a total transaction of $49,146.02. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Achaogen Inc (NASDAQ AKAO) opened at $10.99 on Monday. Achaogen Inc has a 1-year low of $9.83 and a 1-year high of $27.79. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.99 and a quick ratio of 6.99.
AKAO has been the topic of several research reports. HC Wainwright increased their price target on shares of Achaogen from $25.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Mizuho reissued a “buy” rating and set a $28.00 price target on shares of Achaogen in a research report on Monday, October 30th. Zacks Investment Research cut shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Guggenheim reissued a “buy” rating and set a $14.00 price target on shares of Achaogen in a research report on Wednesday, January 10th. Finally, ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $25.60.
TRADEMARK VIOLATION NOTICE: This article was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3223536/kenneth-j-hillan-sells-4606-shares-of-achaogen-inc-akao-stock.html.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.